Page 19 - Read Online

Giovanis et al. Hepatoma Res 2018;4:10 I http://dx.doi.org/10.20517/2394-5079.2018.21 Page 11 of 13

REFERENCES
1. Fischer S, Gillessen S, Rothermundt C. Sequence of treatment in locally advanced and metastatic renal cell carcinoma. Transl Androl
Urol 2015;4:310-25.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017;67:7-30.
3. Zhu AX. Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist 2006;11:790-800.
4. Pinter M, Trauner M, Peck-Radosavljevic M, Sieghart W. Cancer and liver cirrhosis: implications on prognosis and management. ESMO
Open 2016;1:e000042.
5. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C,
Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J,
Group SIS. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
6. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet 2018;391:1301-14.
7. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ,
Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL. Lenvatinib versus sorafenib in first-line treatment of
patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018;391:1163-73.
8. Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross
PJ, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Cheng AL, Llovet JM, Finn RS, LeBerre MA, Baumhauer A, Meinhardt G,
Han G, Investigators R. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a
randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;389:56-66.
9. IPSEN Press Release. Ipsen announces that phase 3 CELESTIAL trial of cabozantinib meets primary endpoint of overall survival in
patients with advanced hepatocellular carcinoma. Available from: https://www.ipsen.com/websites/IPSENCOM-PROD/wp-content/
uploads/2017/10/16115941/16-10-2017-IPSEN-CELESTIAL-OS-EN-FINAL-FINAL.pdf [Last accessed on 18 Apr 2017].
10. BMS Press Release. Bristol-Myers Squibb’s Opdivo® (nivolumab) receives FDA approval for the treatment of hepatocellular carcinoma
patients previously treated with sorafenib. Available from: https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-
squibbs-opdivo-nivolumab-receives-fda-approval-t [Last accessed on 18 Apr 2017].
11. Faivre S, de Gramont A, Raymond E. Learning from 7 years of experience with sorafenib in advanced HCC: sorafenib better than
sorafenib? Target Oncol 2016;11:565-7.
12. Bolondi L, Craxi A, Trevisani F, Daniele B, Di Costanzo GG, Fagiuoli S, Camma C, Bruzzi P, Danesi R, Spandonaro F, Boni C, Santoro A,
Colombo M. Refining sorafenib therapy: lessons from clinical practice. Future Oncol 2015;11:449-65.
13. Lin S, Hoffmann K, Schemmer P. Treatment of hepatocellular carcinoma: a systematic review. Liver Cancer 2012;1:144-58.
14. European Association For The Study Of The Liver. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.
J Hepatol 2012;56:908-43.
15. Salhab M, Canelo R. An overview of evidence-based management of hepatocellular carcinoma: a meta-analysis. J Cancer Res Ther
2011;7:463-75.
16. Raoul JL, Sangro B, Forner A, Mazzaferro V, Piscaglia F, Bolondi L, Lencioni R. Evolving strategies for the management of intermediate-
stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev
2011;37:212-20.
17. Bolondi L, Burroughs A, Dufour JF, Galle PR, Mazzaferro V, Piscaglia F, Raoul JL, Sangro B. Heterogeneity of patients with intermediate
(BCLC-B) hepatocellular carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis 2012;32:348-59.
18. Verslype C, Rosmorduc O, Rougier P. Hepatocellular carcinoma: ESMO–ESDO clinical practice guidelines for diagnosis, treatment and
follow-up. Ann Oncol 2012;23:vii41-8.
19. Sieghart W, Hucke F, Peck-Radosavljevic M. Transarterial chemoembolization: modalities, indication, and patient selection. J Hepatol
2015;62:1187-95.
20. Raoul JL, Gilabert M, Piana G. How to define transarterial chemoembolization failure or refractoriness: a European perspective. Liver
Cancer 2014;3:119-24.
21. Sieghart W, Hucke F, Pinter M, Graziadei I, Vogel W, Muller C, Heinzl H, Trauner M, Peck-Radosavljevic M. The ART of decision
making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatology 2013;57:2261-73.
22. Hucke F, Sieghart W, Pinter M, Graziadei I, Vogel W, Muller C, Heinzl H, Waneck F, Trauner M, Peck-Radosavljevic M. The ART-
strategy: sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE. J
Hepatol 2014;60:118-26.
23. Llovet JM, Finn RS. Negative phase 3 study of (90)Y microspheres versus sorafenib in HCC. Lancet Oncol 2018;19:e69.
24. Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, Sibert A, Bouattour M, Lebtahi R, Allaham W, Barraud H, Laurent
V, Mathias E, Bronowicki JP, Tasu JP, Perdrisot R, Silvain C, Gerolami R, Mundler O, Seitz JF, Vidal V, Aube C, Oberti F, Couturier O,
Brenot-Rossi I, Raoul JL, Sarran A, Costentin C, Itti E, Luciani A, Adam R, Lewin M, Samuel D, Ronot M, Dinut A, Castera L, Chatellier
G, Group ST. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in
locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol
2017;18:1624-36.
25. Chow PK, Gandhi M, Gebski V. The SIRveNIB and SARAH trials and the role of SIR-Spheres(R) Y-90 resin microspheres in the
management of hepatocellular carcinoma. Future Oncol 2017;13:2213-6.
26. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H,
Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular
carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
27. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379:1245-55.